Marci Ann Williams, OTC Orthopaedic Surgery - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 21 Highland Ave Ste 16, Newburyport, MA 01950 Phone: 978-462-7555 |
Dr. Andrew Banos, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Highland Ave Ste 16, Newburyport, MA 01950 Phone: 978-499-4254 |
Dr. Paul S. Chang, D.O. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Highland Ave, Suite 16, Newburyport, MA 01950 Phone: 978-462-7555 Fax: 978-462-9049 |
James J Ford, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Highland Ave, Suite 16, Newburyport, MA 01950 Phone: 978-462-7555 Fax: 978-462-9049 |
Kenneth J Glazier, M.D. Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 21 Highland Ave, Suite 16, Newburyport, MA 01950 Phone: 978-462-7555 Fax: 978-462-9049 |
Stella J Lee, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Highland Ave Ste 16, Newburyport, MA 01950 Phone: 978-462-7555 Fax: 978-462-9049 |
News Archive
Novo Nordisk today announced that Health Canada has approved Levemir® FlexTouch®, a disposable prefilled insulin pen containing Levemir® (insulin detemir). Levemir® FlexTouch® has been designed to improve ease of use for insulin administration and to help decrease barriers to good treatment adherence for Canadians living with type 1 and type 2 diabetes mellitus (diabetes).
BioSpace added Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies from Nebraska to Ohio.
The risks associated with boarding admitted patients in the emergency department – including patient mortality – as well as proposed solutions will be key themes of Scientific Assembly, the annual meeting of the American College of Emergency Physicians. In addition, emergency physicians will present more than 450 research studies during 2010 Research Forum, the premier, annual scientific research event focused on the latest advances in the practice of emergency medicine.
CombinatoRx, Incorporated today announced that the U.S. Food and Drug Administration has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
The poll also shows that, among people with employer-sponsored health insurance, very few respondents would accept changes -; such as a more restricted list of doctors or hospitals -; to their current coverage levels.
› Verified 4 days ago